TapImmune (NASDAQ:MRKR) had its price target cut by Piper Jaffray Companies from $10.00 to $6.00 in a research report sent to investors on Wednesday, The Fly reports. They currently have an overweight rating on the stock. Piper Jaffray Companies also issued estimates for TapImmune’s Q4 2019 earnings at ($0.14) EPS, FY2019 earnings at ($0.50) EPS, Q1 2020 earnings at ($0.14) EPS, Q2 2020 earnings at ($0.16) EPS, Q3 2020 earnings at ($0.17) EPS, Q4 2020 earnings at ($0.19) EPS, FY2020 earnings at ($0.66) EPS, Q1 2021 earnings at ($0.20) EPS, Q2 2021 earnings at ($0.22) EPS, Q3 2021 earnings at ($0.23) EPS and FY2021 earnings at ($0.91) EPS.
Other equities analysts have also issued research reports about the stock. Janney Montgomery Scott reiterated a buy rating on shares of TapImmune in a research report on Sunday, July 21st. ValuEngine upgraded shares of TapImmune from a hold rating to a buy rating in a research report on Wednesday, October 2nd. Nomura reiterated a buy rating and set a $16.00 target price on shares of TapImmune in a research report on Tuesday, August 13th. Finally, Zacks Investment Research lowered shares of TapImmune from a hold rating to a sell rating in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TapImmune currently has an average rating of Buy and an average target price of $10.15.
Shares of TapImmune stock traded up $0.03 during trading on Wednesday, reaching $2.86. 375,700 shares of the company traded hands, compared to its average volume of 378,294. The firm has a market capitalization of $129.40 million, a PE ratio of -1.71 and a beta of 0.16. The company has a 50 day moving average price of $4.31 and a 200-day moving average price of $5.57. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.83 and a quick ratio of 16.85. TapImmune has a 1-year low of $2.69 and a 1-year high of $9.17.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Sell-Side Analysts
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.